Med. praxi. 2018;15(2):71-75 | DOI: 10.36290/med.2018.015

Modern type 2 diabetes treament – practical implications

MUDr. Barbora Doležalová
Fakulta zdravotnických studií, Univerzita Pardubice
IDE CR, s. r. o., Chrudim

The ultimate goal of type 2 diabetes therapy is to prolong and improve life. This goal can be achieved by treating diabetes incontext of other metabolic and vascular comorbidities. Modern diabetes therapy offers improvement in glycaemic control alongwith the reduction of cardiovascular events. The review article focuses on setting therapeutic goals in type 2 diabetes treatment,and major antidiabetes drug classes are described.

Keywords: type 2 diabetes mellitus, pharmacologic treatment, treatment target, cardiovascular safety

Published: May 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Doležalová B. Modern type 2 diabetes treament – practical implications. Med. praxi. 2018;15(2):71-75. doi: 10.36290/med.2018.015.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Česká diabetologická společnost ČLS JEP. Doporučený postup péče o diabetes mellitus 2. typu [online]. 2017-08-01. Dostupné z: www.diab.cz/dokumenty/standard_lecba_dm_typ_II.pdf
    2. ÚZIS ČR. Zdravotnická ročenka České republiky 2016 [online]. ÚZIS ČR, Praha 2017. ISSN 1210-9991. Dostupné z: http://www.uzis.cz/system/files/zdrroccz2016.pdf
    3. Gaede P, Oellgaard J, Carstensen B, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia 2016; 59: 2298. doi: https://doi.org/10.1007/s00125-016-4065-6 Go to original source... Go to PubMed...
    4. OECD. Cardiovascular Disease and Diabetes: Policies for Better Health and Quality of Care, OECD Health Policy Studies [online]. OECD Publishing, Paris 2015. doi: http://dx.doi.org/10.1787/9789264233010-en Go to original source...
    5. de Pablos-Velasco P, et al. Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study. Clin Endocrinol (Oxf). 2014 Jan; 80(1): 47-56. doi: 10.1111/cen.12119 Go to original source... Go to PubMed...
    6. The DCCT/EDIC Study Research Group. Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes. N Engl J Med 2005; 353: 2643-2653. doi: 10.1056/NEJMoa052187 Go to original source... Go to PubMed...
    7. Holman RR, Paul SK, Bethel MA, Neil HAW, Matthews DR. Long-Term Follow-up after Tight Control of Blood Pressure in Type 2 Diabetes. N Eng J Med 2008; 359: 1565-1576. doi: 10.1056/nejmoa0806359 Go to original source...
    8. Tancredi M, et al. Excess Mortality among Persons with Type 2 Diabetes. N Engl J Med 2015; 373: 1720-1732. Go to original source...
    9. Genuth S, Ismail-Beigi F. Clinical Implications of the ACCORD Trial. The Journal of Clinical Endocrinology & Metabolism 2012, 97(1): 41-48. doi: https://doi.org/10.1210/jc.2011-1679 Go to original source...
    10. Inzucchi SE, et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient - Centered Approach. Diabetes Care 2015; 38: 140-149. doi: 10.2337/dc14-2441 Go to original source...
    11. AACE/ACE Comprehensive Type 2 Diabetes Management Algorithm 2017 [online]. Endocr Pract 2017. doi: 10.4158/EP161682.CS
    12. Svačina Š. Antidiabetika - historie, současnost a perspektivy. Praha: Axonite CZ 2016.
    13. American Diabetes Association. Standards of Medical Care in Diabetes - 2018. Pharmacologic Approaches to Glycemic Treatment. Diabetes Care 2018; 41(Supplement 1): S73-S85. doi: https://doi.org/10.2337/dc18-S008 Go to original source... Go to PubMed...
    14. Schwartz SS, et al. The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the b-Cell-Centric Classification Schema. Diabetes Care 2016; 39: 179-186. doi: 10.2337/dc15-1585 Go to original source...
    15. Vaccaro O, Masulli M, Nicolucci A, et al. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial [online]. Lancet Diabetes Endocrinol 2017. doi: http://dx.doi.org/10.1016/S2213-8587(17)30317-0 Go to original source...
    16. Patel A, et al. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. The New England Journal of Medicine. 2008. 358(24): 2560-2572. Go to original source...
    17. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311-322. Go to original source...
    18. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-2128. Go to original source...
    19. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017; 377: 644-657. doI: 10.1056/NEJMoa1611925 Go to original source...
    20. Sattar, N, McLaren J, Kristensen SL, et al. SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia 2016; 59: 1333. doi:10.1007/s00125-016-3956-x Go to original source...
    21. Ponikowski P, et al. ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Eur Heart J 2016; 37(27): 2129-2200. doi: https://doi.org/10.1093/eurheartj/ehw128 Go to original source...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.